Senhwa Completes Enrollment of a Phase 2 Investigator Initiated Trial of Silmitasertib as Novel Oral Drug for COVID-19 |
| August 16, 2021 | August 2021 Bond Updates |
|
TAIPEI and SAN DIEGO, Aug. 16, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focused on human efficacy and innovation of first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, today announced that its novel oral drug,... |
| View more at: https://www.prnewswire.com:443/news-releases/senhwa-completes-enrollment-of-a-phase-2-investigator-initiated-trial-of-silmitasertib-as-novel-oral-drug-for-covid-19-301355617.html |
| Related News |